APL during gefitinib treatment for non-small-cell lung cancer.
Uchida
Akiko
A
Matsuo
Keitaro
K
Tanimoto
Mitsune
M
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D000077156:Gefitinib; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib